{"id":"NCT01108510","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2011-11","completion":"2015-04","firstPosted":"2010-04-22","resultsPosted":"2014-10-28","lastUpdate":"2016-05-23"},"enrollment":698,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV","HIV Infections"],"interventions":[{"type":"DRUG","name":"COBI","otherNames":["Tybost®","GS-9350"]},{"type":"DRUG","name":"RTV","otherNames":["Norvir®"]},{"type":"DRUG","name":"ATV","otherNames":["Reyataz®"]},{"type":"DRUG","name":"FTC/TDF","otherNames":["Truvada®"]},{"type":"DRUG","name":"COBI placebo","otherNames":[]},{"type":"DRUG","name":"RTV placebo","otherNames":[]}],"arms":[{"label":"ATV+COBI+FTC/TDF","type":"EXPERIMENTAL"},{"label":"ATV+RTV+FTC/TDF","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) fixed-dose combination (FDC) versus ritonavir-boosted atazanavir (ATV+RTV) plus FTC/TDF FDC in HIV-1 infected, antiretroviral treatment-naive adults.\n\nParticipants will be randomized in a 1:1 ratio. Randomization will be stratified by HIV-1 RNA level (≤ 100,000 copies/mL or \\> 100,000 copies/mL) at screening.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"ATV+COBI+FTC/TDF","deltaMin":85.2,"sd":null},{"arm":"ATV+RTV+FTC/TDF","deltaMin":87.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":13},"locations":{"siteCount":134,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Denmark","Dominican Republic","France","Germany","Italy","Mexico","Netherlands","Portugal","Puerto Rico","Spain","Switzerland","Thailand","United Kingdom"]},"refs":{"pmids":["23532097","26181707","27774892"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":344},"commonTop":["Diarrhoea","Ocular icterus","Nasopharyngitis","Jaundice","Nausea"]}}